All In Biotech

Drug Trial Radar · NCT06843447

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

605

Planned (sponsor's estimate)

Start

Apr 15, 2025

Primary completion

Mar 27, 2029

Study completion Feb 7, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Feb 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.

Conditions

  • Ovarian Cancer Recurrent

Interventions

  • Raludotatug DeruxtecanBiological

    IV infusion on Day 1 of every 3-week cycle.

  • CarboplatinDrug

    IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

  • PaclitaxelDrug

    IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

  • BevacizumabBiological

    IV infusion on Day 1 of every 3-week cycle.

  • Rescue MedicationDrug

    Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

  • PembrolizumabBiological

    IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

  • GemcitabineDrug

    IV injection on days 1 and 8 of each 3-week Cycle

  • Pegylated liposomal doxorubicinDrug

    IV injection administered on Day 1 of each 4-week cycle

  • MK-2010Drug

    IV infusion on Day 1 of every 3-week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)Time frame: Up to 21 days
  2. Part 1: Number of Participants with One or More Adverse Events (AEs)Time frame: Up to approximately 3 years
  3. Part 1: Number of Participants who Discontinue Study Intervention Due to an AETime frame: Up to approximately 3 years
  4. Part 2: Objective Response Rate (ORR)Time frame: Up to approximately 3 years
  5. Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2Time frame: Up to approximately 3 years

Locations

42 sites in 9 countries. Site status is shown where the registry gives one.

  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)

    New Haven, Connecticut · Recruiting

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0009)

    Louisville, Kentucky · Recruiting

  • TRIALS 365 ( Site 0020)

    Shreveport, Louisiana · Recruiting

  • Dana-Farber Cancer Institute ( Site 0015)

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 0003)

    New York, New York · Recruiting

  • OU Health University of Oklahoma Medical Center ( Site 7000)

    Oklahoma City, Oklahoma · Recruiting

  • Texas Oncology - DFW ( Site 8000)

    Fort Worth, Texas · Recruiting

  • Houston Methodist Hospital ( Site 0010)

    Houston, Texas · Completed

  • START Mountain Region ( Site 0008)

    West Valley City, Utah · Recruiting

  • University of Virginia Health System ( Site 0011)

    Charlottesville, Virginia · Recruiting

  • Western Health-Sunshine & Footscray Hospitals ( Site 1002)

    St Albans, Victoria, Australia · Recruiting

  • Princess Margaret Cancer Centre ( Site 0101)

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier de l'Université de Montréal ( Site 0102)

    Montreal, Quebec, Canada · Recruiting

  • McGill University Health Centre ( Site 0100)

    Montreal, Quebec, Canada · Recruiting

  • Rambam Health Care Campus ( Site 0202)

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center ( Site 0201)

    Jerusalem, Israel · Recruiting

  • Rabin Medical Center ( Site 0203)

    Petah Tikva, Israel · Recruiting

  • Sheba Medical Center ( Site 0200)

    Ramat Gan, Israel · Recruiting

  • Seoul National University Hospital ( Site 2000)

    Seoul, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System ( Site 2002)

    Seoul, South Korea · Recruiting

  • Asan Medical Center ( Site 2003)

    Seoul, South Korea · Recruiting

  • Samsung Medical Center ( Site 2001)

    Seoul, South Korea · Recruiting

  • National Cancer Center ( Site 2004)

    Goyang-si, Kyonggi-do, South Korea · Recruiting

  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)

    Barcelona, Spain · Recruiting

  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre ( Site 0304)

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen de la Victoria ( Site 0306)

    Málaga, Spain · Recruiting

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0302)

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

  • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)

    Majadhonda, Madrid, Spain · Recruiting

  • Clinica Universidad de Navarra ( Site 0301)

    Madrid, Madrid, Comunidad de, Spain · Recruiting

  • Hospital General Universitario de Valencia ( Site 0305)

    Valencia, Valenciana, Comunitat, Spain · Recruiting

  • HOCH Health Ostschweiz ( Site 0801)

    Sankt Gallen, Switzerland · Recruiting

  • University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)

    Basel, Canton of Basel-City, Switzerland · Recruiting

  • CHUV (centre hospitalier universitaire vaudois) ( Site 0800)

    Lausanne, Canton of Vaud, Switzerland · Recruiting

  • National Taiwan University Hospital ( Site 3001)

    Taipei, Taiwan · Recruiting

  • Chang Gung Medical Foundation-Linkou Branch ( Site 3002)

    Taoyuan, Taiwan · Recruiting

  • The Christie NHS Foundation Trust ( Site 0405)

    Manchester, United Kingdom · Recruiting

  • University Hospitals Sussex NHS Foundation Trust ( Site 0404)

    Brighton, East Sussex, United Kingdom · Recruiting

  • Royal Marsden Hospital ( Site 0402)

    Fulham, England, United Kingdom · Recruiting

  • The Royal Marsden NHS Foundation Trust. ( Site 0403)

    Sutton, England, United Kingdom · Recruiting

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.